Sarah Moberley

Sarah Moberley

Auto-generated profile, based on publicly available information

Sarah Moberley

Hunter New England Population Health, NSW, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2013 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SMSarah Moberley
Sarah Moberley
JHJohn Holden
John Holden
DTDavid Paul Tatham
David Paul Tatham
RARoss M Andrews
Ross M Andrews

23 January 2008
Verified
Reference Entry
Closed access
PDF file
SMSarah Moberley
Sarah Moberley
JHJohn Holden
John Holden
DTDavid Paul Tatham
David Paul Tatham
RARoss M Andrews
Ross M Andrews

1 March 2005 in Emerging Infectious Diseases
Verified
Journal Article
Open access
BTBarbara L. Telfer
Barbara L. Telfer
SMSarah A. Moberley
Sarah A. Moberley
KHKrishna Hort
Krishna Hort
JBJames M. Branley
James M. Branley
DDDominic E. Dwyer
Dominic E. Dwyer
JMJeremy M. McAnulty
Jeremy M. McAnulty
In autumn 2002, an outbreak of probable psittacosis occurred among residents of the Blue Mountains district, Australia. We conducted a case-control study to determine independent risk factors for psittacosis by comparing exposures between hospitalized patients and other residents selected randomly from the telephone directory. Of the 59 case-patients with laboratory results supportive of psittacosis, 48 participated in a case-control study with 310 controls. Independent risk factors were residence in the upper Blue Mountains (odds ratio [OR] = 15.2, 95% confidence interval [CI] 5.6–41.7), age of 50–64 years (OR = 3.9, 95% CI 1.5–10.5), direct contact with wild birds (OR = 7.4, 95% CI 2.5–22), and mowing lawns without a grass catcher (OR = 3.2, 95% CI 1.3–8.0). Protective equipment is recommended for residents in areas frequented by free-ranging birds if contact with birds and their droppings is likely when performing outdoor activities such as lawn mowing.

1 September 2014 in Vaccine
Verified
Journal Article
Open access
PCPatrick Cashman
Patrick Cashman
SMSarah Moberley
Sarah Moberley
CDCraig Dalton
Craig Dalton
JSJody Stephenson
Jody Stephenson
EEElissa Elvidge
Elissa Elvidge
David N DurrheimDavid N Durrheim
David N Durrheim
Vaxtracker is a web based survey for active post marketing surveillance of Adverse Events Following Immunisation. It is designed to efficiently monitor vaccine safety of new vaccines by early signal detection of serious adverse events. The Vaxtracker system automates contact with the parents or carers of immunised children by email and/or sms message to their smart phone. A hyperlink on the email and text messages links to a web based survey exploring adverse events following the immunisation. The Vaxtracker concept was developed during 2011 (n=21), and piloted during the 2012 (n=200) and 2013 (n=477) influenza seasons for children receiving inactivated influenza vaccine (IIV) in the Hunter New England Local Health District, New South Wales, Australia. Survey results were reviewed by surveillance staff to detect any safety signals and compare adverse event frequencies among the different influenza vaccines administered. In 2012, 57% (n=113) of the 200 participants responded to the online survey and 61% (290/477) in 2013. Vaxtracker appears to be an effective method for actively monitoring adverse events following influenza vaccination in children.

1 November 2015 in Vaccine
Verified
Journal Article
Open access
MBMICHAEL BINKS
MICHAEL BINKS
SMSarah A. Moberley
Sarah A. Moberley
ABAnne Balloch
Anne Balloch
ALAmanda J. Leach
Amanda J. Leach
SNSandra Nelson
Sandra Nelson
RARoss M. Andrews
Ross M. Andrews
We assessed maternal 23-valent pneumococcal polysaccharide (23vPPV) vaccine efficacy (VE) against middle ear disease and pneumococcal carriage amongst Australian Indigenous infants. In an open label, allocation concealed, outcome-assessor blinded, community stratified, randomised controlled trial, healthy pregnant Indigenous women aged 17-39 years in the Northern Territory of Australia received the 23vPPV (1:1:1) at: 30-36 weeks gestation, birth, or were unvaccinated (ClinicalTrials.gov NCT00714064). Co-primary outcomes were the point prevalences of infant middle ear disease and 23vPPV-type carriage at age 7 months. The consent rate was 50% (313/632). Among 227 eligible participants randomised, retention rates were 86% (66/77) controls; 89% (67/75) pregnancy vaccinees; 88% (66/75) birth vaccinees. At infant age 7 months, ear disease prevalence was: 71% (47/66) controls, 63% (42/67) pregnancy vaccinees, 76% (50/66) birth vaccinees; and 23vPPV-type carriage was: 26% (17/66) controls, 18% (12/67) pregnancy vaccinees, 18% (12/66) birth vaccinees. For pregnancy vaccinees, VE was 12% (95% CI -12% to 31%) against infant ear disease and 30% (95% CI -34% to 64%) against 23vPPV-type carriage. In a post-hoc analysis, VE against infant ear disease concurrent with carriage of 23vPPV or related types was 51% (95% CI -2% to 76%). There were no serious adverse effects following receipt of the 23vPPV in pregnancy or at birth. In a high risk population, our study was unable to demonstrate efficacy of 23vPPV in pregnancy against the co-primary outcomes of either all-cause infant ear disease or 23vPPV-type nasopharyngeal carriage at age 7 months. Efficacy against ear disease concurrent with carriage of vaccine-related serotypes (a more specific outcome) suggests 23vPPV in pregnancy may complement childhood pneumococcal vaccination programs.

18 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EMElizabeth A. McCarthy
Elizabeth A. McCarthy
HSHamsa L. Subramaniam
Hamsa L. Subramaniam
MPMargaret L. Prust
Margaret L. Prust
MPMarta R. Prescott
Marta R. Prescott
FMFelton Mpasela
Felton Mpasela
SMSarah Moberley
Sarah Moberley
In urban areas, crowded HIV treatment facilities with long patient wait times can deter patients from attending their clinical appointments and picking up their medications, ultimately disrupting patient care and compromising patient retention and adherence. Formative research at eight facilities in Lusaka revealed that only 46% of stable HIV treatment patients were receiving a three-month refill supply of antiretroviral drugs, despite it being national policy for stable adult patients. We designed a quality improvement intervention to improve the operationalization of this policy. We conducted a cluster-randomized controlled trial in sixteen facilities in Lusaka with the primary objective of examining the intervention’s impact on the proportion of stable patients receiving three-month refills. The secondary objective was examining whether the quality improvement intervention reduced facility congestion measured through two proxy indicators: daily volume of clinic visits and average clinic wait times for services. The mean change in the proportion of three-month refills among control facilities from baseline to endline was 10% (from 38% to 48%), compared to a 25% mean change (an increase from 44% to 69%) among intervention facilities. This represents a significant 15% mean difference (95% CI: 2%-29%; P = 0.03) in the change in proportion of patients receiving three-month refills. On average, control facilities had 15 more visits per day in the endline than in the baseline, while intervention facilities had 20 fewer visits per day in endline than in baseline, a mean difference of 35 fewer visits per day (P = 0.1). The change in the mean facility total wait time for intervention facilities dropped 19 minutes between baseline and endline when compared to control facilities (95% CI: -10.2–48.5; P = 0.2). A more patient-centred service delivery schedule of three-month prescription refills for stable patients is viable. We encourage the expansion of this sustainable intervention in Zambia’s urban clinics.